Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil

Current Medical Research and Opinion

Volumn 23, Issue 5, 2007, Pages 1187-1197

  Weycker, Derek ^a   Taneja, Charu ^a   Edelsberg, John ^a   Erder, M Haim ^b   Schmitt, Frederick A ^c   Setyawan, Juliana ^b   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Cost benefit analysis; Donepezil; Memantine

Indexed keywords

DONEPEZIL; MEMANTINE; PLACEBO;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DATA BASE; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; MONOTHERAPY; MORTALITY; SENSITIVITY ANALYSIS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CLINICAL TRIALS, PHASE III; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDANS; MALE; MEMANTINE; MODELS, ECONOMETRIC; NOOTROPIC AGENTS; PIPERIDINES;

EID: 34249037440     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X188071     Document Type: Conference Paper

References (33)

1. Cummings, JL, Cole G. Alzheimer disease. JAMA 2002;287:2335-8
2. Brookmeyer R, Corrada MM, Curriero FC, Kawas C. Survival following a diagnosis of Alzheimer disease. Arch Neurol 2002;59:1764-7
3. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: Prevalence estimates using the 2000 Census. Arch Neurol 2003;60:1119-22
4. Leon J, Cheng CK, Neumann PJ. Alzheimer's disease care: costs and potential savings. Health Affairs 1998;17:206-16
5. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA 2004;291: 317-24
6. Jonsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. Am J Geriatr Pharmacother 2005;3:77-86
7. Francois C, Sintonen H, Sulkava R, Rive B. Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease: a Markov model in Finland. Clin Drug Invest 2004; 24:373-84
8. Jones, RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 2004;21:607-20
9. United States General Accounting Office. Alzheimer's disease: estimates of prevalence in the United States. GAO/HEHS 1998;16:1-45
10. Reisberg B, Doody R, Stöffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006;63:49-54
11. Plosker GL, Lyseng-Williamson KA. Memantine: a pharmaco-economic review of its use in moderate-to-severe Alzheimer's disease. Pharmacoeconomics 2005;23:193-206
12. US Bureau of Labor Statistics. Consumer Price Indexes (CPI]. Available at: US Bureau of Labor Statistics. Consumer Price Indexes (CPI). Available at: http://www.bls.gov/cpi/home.htm [Last accessed 27 November 2006]
13. US Bureau of Labor Statistics. Employer costs for employee compensation. Available at: http://www.bls.gov/ecthome.htm [Last accessed 27 November 2006]
14. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8
15. Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and assessment of longitudinal change in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997;Suppl 2:S51-6
16. Panisset M, Roudier M, Saxton J, Boiler F. Severe impairment battery: a neuropsychological test for severely demented patients. Arch Neurol 1994;51:41-5.
17. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-20
18. Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999;52:1138-45
19. National Center for Health Statistics. Vital Statistics of the United States, 2001. Vol II, Mortality, Part B. Washington, DC: Public Health Service: 2001
20. Evans DA, Smith LA, Scherr PA, et al. Risk of death from Alzheimer's disease in a community population of older persons. Am J Epidemiol 1991;134:403-12
21. Neumann PJ, Sandberg EA, Araki SS, et al. A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. Med Decis Making 2000;20:413-22
22. Furlong W, Feeny D, Torrance GW, et al. Multiplicative multi-attribute utility function for the Health Utilities Index Mark 2 (HUI3) System: a technical report. McMaster University Centre for Health Economics and Policy Analysis Working Paper. No. 98-11, 1998.
23. Badawi S, Convington TR, eds. Pharmacy reimbursement rates stabilize. Academy of Managed Care Providers News 2001; 3:2
24. Drug Topics Redbook. Monvale, NJ: Medical Economics, Inc. 2003
25. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-28
26. Ubel PA, Hirth R, Chernew M, Fendrick MA. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:1637-41
27. Laupacis A, Feeny D, Destsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-81
28. Wimo A, Winblad B, Stoffler A, et al. Resource utilization and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003;21:327-40
29. Mendiondo MS, Ashford JW, Krysico RJ, Schmitt FA. Modelling mini-mental state examination changes in Alzheimer's disease. Statist Med 2000; 19:1607-16
30. Juva K, Sulkava R, Erkinjuntti T, et al. Staging the severity of dementia: comparison of clinical (CDR, DSM-III-R), functional (ADL, IADL), and cognitive (MMSE) scales. Acta Neurol Scand 1994;90:293-8
31. Perneczky R, Wagenpfeil S, Komossa K, et al. Mapping scores onto stages: mini-mental state examination and clinical dementia rating. J Geriatr Psychiatry 2006;14: 139-44
32. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-45
33. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease. Arch Intern Med 1998;158:1021-31